Journal of Medicinal Chemistry · 2007 · 49 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsDrug-receptor InteractionsEnzyme InhibitionLigand BindingMolecular DockingReceptor-ligand InteractionsStructure-activity Relationship AnalysisElectronic State InteractionsMolecular Property-based DesignProtein-ligand ComplexesSar InterpretationSteric-electronic InteractionsStructure - Pharmacokinetic Relationship AnalysisStructure-activity Relationship ModelingTarget-ligand Interactions
Factor Xa inhibitory activities for a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides with different P1 groups are described. These data provide insight into binding interactions within the S1 primary specificity pocket; rationales are presented for the derived SAR on the basis of electronic interactions through crystal structures of fXa-ligand complexes and molecular modeling studies. A good correlation between in vitro anticoagulant activities with lipophilicity and the extent of human serum albumin binding is observed within this series of potent fXa inhibitors. Pharmacokinetic profiles in rat and dog, together with selectivity over other trypsin-like serine proteases, identified 1f as a candidate for further evaluation.
15
Hematology: Basic Principles and Practice
Toby Simon · Transfusion · 2001 · 744 citations
Role of the thrombin receptor in development and evidence for a second receptor
Andrew J. Connolly, Hiroaki Ishihara, Mark L. Kahn et al. · Nature · 1996 · 509 citations
Klára Valkó, Shenaz Nunhuck, Chris Bevan et al. · Journal of Pharmaceutical Sciences · 2003 · 331 citations